NCT07404865Phase 3Recruiting

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-12Estimated

Enrollment · participants250Estimated

Source updated2026-08-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-02 · 1 field changed

Primary completion date changed

− Before

~~Jun 2028~~

+ After

Dec 2028

Check registry source

Posted 2026-03-16 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Primary Sjogren's Disease

Treatments or interventions studied

TelitaciceptBiologicalAlso known as RC18, RC18-L
PlaceboDrug

Primary outcomes · main study measures

measure: To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.; description: Change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.; timeFrame: Week 48

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history